COMPUESTOS HETEROAROMATICOS Y SU USO COMO LIGANDOS DE DOPAMINA D1
SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE OTROS; Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO; L1 ES O, S, C(=O), CH(OH), ENTRE OTROS; T1 E...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | Spanish |
Published |
17.03.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE OTROS; Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO; L1 ES O, S, C(=O), CH(OH), ENTRE OTROS; T1 ES H, OH, HALOGENO, CN, ALQUILO C1-C2; X1 ES O, S, NH, N(ALQUILO C1-C4), ENTRE OTROS; X2 ES N O C-T2; X3 ES N O C-T3; X4 ES N O C-T4, DONDE T2, T3 Y T4 SON CADA UNO H, OH, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (+)-1,5-DIMETIL-6-[2-METIL-4-(TIENO[3,2-d]PIRIMIDIN-4-ILOXI)FENIL]PIRIMIDIN-2,4(1H,3H)-DIONA; 4,6-DIMETIL-5-[2-METIL-4-([1,2]TIAZOLO[5,4-c]PIRIDIN-7-ILOXI)FENIL]PIRIDAZIN-3(2H)-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE DOPAMINA D1 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, DEFICIENCIA COGNITIVA, ENFERMEDAD DE PARKINSON, ANSIEDAD
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression. |
---|---|
AbstractList | SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE OTROS; Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO; L1 ES O, S, C(=O), CH(OH), ENTRE OTROS; T1 ES H, OH, HALOGENO, CN, ALQUILO C1-C2; X1 ES O, S, NH, N(ALQUILO C1-C4), ENTRE OTROS; X2 ES N O C-T2; X3 ES N O C-T3; X4 ES N O C-T4, DONDE T2, T3 Y T4 SON CADA UNO H, OH, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (+)-1,5-DIMETIL-6-[2-METIL-4-(TIENO[3,2-d]PIRIMIDIN-4-ILOXI)FENIL]PIRIMIDIN-2,4(1H,3H)-DIONA; 4,6-DIMETIL-5-[2-METIL-4-([1,2]TIAZOLO[5,4-c]PIRIDIN-7-ILOXI)FENIL]PIRIDAZIN-3(2H)-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE DOPAMINA D1 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, DEFICIENCIA COGNITIVA, ENFERMEDAD DE PARKINSON, ANSIEDAD
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression. |
Author | DOUNAY, Amy Beth SUBRAMANYAM, Chakrapani GRAY, David Lawrence Firman ZHANG, Lei MENTE, Scot Richard EFREMOV, Ivan Viktorovich DAVOREN, Jennifer Elizabeth |
Author_xml | – fullname: MENTE, Scot Richard – fullname: EFREMOV, Ivan Viktorovich – fullname: ZHANG, Lei – fullname: GRAY, David Lawrence Firman – fullname: DOUNAY, Amy Beth – fullname: SUBRAMANYAM, Chakrapani – fullname: DAVOREN, Jennifer Elizabeth |
BookMark | eNrjYmDJy89L5WRwdPb3DQh1DQ7xD1bwcA1xDfJ3DPL3dQzxdAYKRCoEhyqEBvsrABX5K_h4ujv6uQCFXVwVXPwDHH09_RwVXAx5GFjTEnOKU3mhNDeDoptriLOHbmpBfnxqcUFicmpeakl8gKuRgaG5gYGBhaOhMTFqAPAvLH0 |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | PE20170008A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_PE20170008A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 13:55:43 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Spanish |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_PE20170008A13 |
Notes | Application Number: PE2016002125 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170317&DB=EPODOC&CC=PE&NR=20170008A1 |
ParticipantIDs | epo_espacenet_PE20170008A1 |
PublicationCentury | 2000 |
PublicationDate | 20170317 |
PublicationDateYYYYMMDD | 2017-03-17 |
PublicationDate_xml | – month: 03 year: 2017 text: 20170317 day: 17 |
PublicationDecade | 2010 |
PublicationYear | 2017 |
RelatedCompanies | PFIZER INC |
RelatedCompanies_xml | – name: PFIZER INC |
Score | 3.0757868 |
Snippet | SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON CADA UNO H, OH, HALOGENO, NH2, ENTRE... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | COMPUESTOS HETEROAROMATICOS Y SU USO COMO LIGANDOS DE DOPAMINA D1 |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170317&DB=EPODOC&locale=&CC=PE&NR=20170008A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOqbokbxIzUxe1tkbNDtgZjSFsG4dWGbwSfCvhJ9ACIz_vveJogv-tbeNU3b5Ne7tne_Atw6ZmJSIzZ1u23lupUmVJ_RrKWjsU9anXbenVUEpq7XHUbW46QzqcHbJhem4gn9rMgREVEJ4r2o9uvl9hJLVLGVq7v4FUWL-0HYE9r6dGyUbOxUE_2e9JVQXOO850vNG3_r0N4xPCntoBtNSzTI536ZlbL8bVIGh7DrY2_z4ghq2aoB-3zz81oD9tz1gzcW19hbHQPjyvUjGYQqIEOJXqhiY-WycMRR8EKCiESBIthIkafRA_MEioUkQvnMHXmMCOMEbgYy5EMdxzL9mfjUl9thm6dQny_m2RmQFHHnGJ3MLlk8Z-3cyY3UdqzUyVt2bCf0HJp_99P8T3kBB2WljLEy6CXUi_eP7AqNbhFfV6v1BT03fsg |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOKbokbxqyZmb4uMDbY9EFPW4qZsXdhm8Imwr0QfgMiM_763CeKLvjV3zaVt8utd27tfAW5NNVF1JVZlo6PlspYmujzTs7aMzj5pdzt5b1YRmLpez460x0l3UoO3TS1MxRP6WZEjIqISxHtR7dfL7SUWq3IrV3fxK4oW98Owz6T16Vgp2dh1iQ363BdMWJJl9X0ueeNvHfo7iielHQyx9RIN_HlQVqUsf7uU4QHs-mhtXhxCLVs1oWFtfl5rwp67fvDG5hp7qyOglnD9iAehCIjNMQoVdCxcGjoWCl5IEJEoEAQ7CTJyHqjHUMw4YcKnruNRwpRjuBny0LJlHMv0Z-JTn2-HrZ5Afb6YZ6dAUsSdqXQzo2TxnHVyM1dSw9RSM28bsZHoZ9D6207rP-U1NOzQHU1Hjvd0Dvulosy3UvQLqBfvH9klOuAivqpW7gta4YG7 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COMPUESTOS+HETEROAROMATICOS+Y+SU+USO+COMO+LIGANDOS+DE+DOPAMINA+D1&rft.inventor=MENTE%2C+Scot+Richard&rft.inventor=EFREMOV%2C+Ivan+Viktorovich&rft.inventor=ZHANG%2C+Lei&rft.inventor=GRAY%2C+David+Lawrence+Firman&rft.inventor=DOUNAY%2C+Amy+Beth&rft.inventor=SUBRAMANYAM%2C+Chakrapani&rft.inventor=DAVOREN%2C+Jennifer+Elizabeth&rft.date=2017-03-17&rft.externalDBID=A1&rft.externalDocID=PE20170008A1 |